Stockscreener 앱 받기
39.74
5.69%
2.14
시장 영업 전:
39.44
-0.30
-0.75%
Moonlake Immunotherapeutics 주식(MLTX)의 최신 뉴스
In the Green: MoonLake Immunotherapeutics (MLTX) Closes at 37.60, Up/Down -4.24 from Previous Day - DWinneX
MoonLake Immunotherapeutics’ SWOT analysis: biopharma stock faces challenges and opportunities - Investing.com
MoonLake Immunotherapeutics’ (MLTX) “Buy” Rating Reiterated at Needham & Company LLC - Defense World
(MLTX) Investment Analysis - news.stocktradersdaily.com
MoonLake Immunotherapeutics: Promising Clinical Updates and Market Potential Support Buy Rating - TipRanks
RBC Capital Reaffirms Their Buy Rating on MoonLake Immunotherapeutics (MLTX) - The Globe and Mail
MoonLake Immunotherapeutics (MLTX) receives an Outperform rating from RBC Capital Mkts - knoxdaily.com
MoonLake Immunotherapeutics Shares Surge Ahead of Key Event - TipRanks
MoonLake Immunotherapeutics price target raised to $85 from $81 at BTIG - TipRanks
MoonLake Immunotherapeutics: Promising Developments and Financial Strength Justify Buy Rating - TipRanks
BTIG Boosts Price Target for MoonLake Immunotherapeutics (MLTX) to $85 | MLTX Stock News - GuruFocus
MoonLake Immunotherapeutics: Promising Developments and Strategic Positioning Justify Buy Rating - TipRanks
MoonLake Immunotherapeutics: Promising Clinical Trials and Market Potential Drive Buy Rating - TipRanks
Ratio Analysis: Unpacking MoonLake Immunotherapeutics (MLTX)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
MoonLake Immunotherapeutics Hosts Capital Markets Day - TipRanks
Geode Capital Management LLC Purchases 540 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
LPL Financial LLC Buys 1,332 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - American Banking and Market News
LPL Financial LLC Purchases 1,332 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 - GlobeNewswire
Is MoonLake Immunotherapeutics (MLTX) Among the Best Guru Stocks to Buy According to Wall Street Analysts? - Insider Monkey
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Average Rating of “Buy” from Brokerages - Defense World
11 Best Guru Stocks to Buy According to Wall Street Analysts - Insider Monkey
(MLTX) On The My Stocks Page - news.stocktradersdaily.com
Psoriasis Market Outlook in the 7MM Through 2034: In-Depth Analysis by Psoriasis Type | DelveInsight - GlobeNewswire Inc.
Psoriasis Market Outlook in the 7MM Through 2034: In-Depth Analysis by Psoriasis Type | DelveInsight - GlobeNewswire
How nanobodies will revolutionize immunotherapyBeyond Biotech - Beyond Biotech - the podcast from Labiotech
We Think MoonLake Immunotherapeutics (NASDAQ:MLTX) Can Afford To Drive Business Growth - simplywall.st
Oversold Conditions For MoonLake Immunotherapeutics (MLTX) - Nasdaq
4,500 Shares in MoonLake Immunotherapeutics (NASDAQ:MLTX) Purchased by KLP Kapitalforvaltning AS - Defense World
Sei Investments Co. Acquires 1,202 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
MoonLake Immunotherapeutics (NASDAQ:MLTX) Sets New 1-Year Low – Here’s What Happened - Defense World
MoonLake Immunotherapeutics: A Buy At Dips (NASDAQ:MLTX) - Seeking Alpha
MoonLake Immunotherapeutics’ $500 Million Debt Financing with Hercules Capital - Global Legal Chronicle
MoonLake Immunotherapeutics Term Loan Facility - Leerink Partners
Cantor Fitzgerald maintains Overweight on Moonlake stock - Investing.com Australia
MoonLake secures up to $500 million financing; research update - The Pharma Letter
Cantor Fitzgerald maintains Overweight on Moonlake stock By Investing.com - Investing.com Canada
MoonLake secures $500m for lead drug, plus other financings - Pharmaphorum
Switzerland: MoonLake secures up to US$500m in non-dilutive financing - Investors in Healthcare
MoonLake in US$500m debt deal with Hercules Capital - European Biotechnology Magazine
MoonLake secures up to $500M in financing from Hercules Capital - MSN
MoonLake discloses up to $500M in financing; OSR’s deal with innovation fund - Endpoints News
MoonLake Obtains $500 Million Facility From Hercules Capital - MarketScreener
MoonLake secures hefty financing package to fuel sonelokimab's path to market - FirstWord
MoonLake Immunotherapeutics secures up to $500M in non-dilutive financing - TipRanks
MoonLake Immunotherapeutics Secures $500M Financing for Growth - TipRanks
Moonlake Secures Up To $500 Million In Non-Dilutive Financing From Hercules Capital And Announces A Capital Markets Update On April 29 To Provide Important Clinical Updates - MarketScreener
MoonLake Secures up to $500 Million in Non-Dilutive - GlobeNewswire
MoonLake Lands Massive $500M Deal: Game-Changing Clinical Updates Coming April 29 - Stock Titan
MoonLake (MLTX) Secures $500M Non-Dilutive Financing to Advance Sonelokimab - GuruFocus
How the (MLTX) price action is used to our Advantage - news.stocktradersdaily.com
Teacher Retirement System of Texas Has $354,000 Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
MoonLake’s 37% decline validates InvestingPro’s overvaluation warning By Investing.com - Investing.com Australia
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Rating of “Buy” from Analysts - Defense World
Long Term Trading Analysis for (MLTX) - Stock Traders Daily
5.73%
1.07%
자본화:
|
볼륨(24시간):